Increased plasma levels of 6-oxo-prostaglandin F1 alpha, a stable metabolite of prostacyclin, in acute kidney transplant rejection.
In 30 patients after kidney transplantation, 6-oxo-PGF1 alpha was examined in unextracted plasma by a specific radioimmunoassay. The material was divided into three groups. Patients with acute transplant rejection showing the highest 6-oxo-PGF1 alpha levels, patients with delayed transplant rejection having significantly lower plasma values and a third group of patients with stable transplant function. In these patients the plasma 6-oxo-PGF1 alpha-values were below the lower limit of detection (70 pg/ml). The enhanced 6-oxo-PGF1 alpha during rejection crisis could be interpreted as a self protection mechanism of vascular tissue which is, however, not sufficient in many cases, to prevent the irreversible rejection of the transplant.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000208:Acute Disease; D000328:Adult; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D011453:Prostaglandins / Q000378:metabolism*
D011453:Prostaglandins; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol